How should a pregnant woman presenting with fever, interstitial lung disease on imaging, and a positive antinuclear antibody be managed?

Management of Fever, Interstitial Lung Disease, and Positive ANA in Pregnancy

Immediate Multidisciplinary Consultation

This pregnant patient requires urgent evaluation by both a pulmonologist and a high-risk obstetrician to determine the underlying cause of her interstitial lung disease and guide treatment decisions. 1

The combination of fever, ILD on imaging, and positive ANA suggests either:

• Autoimmune-featured ILD (AIF-ILD) with systemic inflammation
• Connective tissue disease-associated ILD (CTD-ILD)
• Infection complicating pre-existing ILD

Diagnostic Workup Priority

Assess Disease Severity Immediately

• Obtain pulmonary function tests (PFTs) including spirometry and diffusing capacity to stratify disease severity, as very severe ILD (vital capacity ≤1.5L or DLCO ≤50% predicted) carries the highest risk of adverse pregnancy outcomes. 2, 3
• Perform exercise oximetry or ambulatory oxygen saturation monitoring, since exercise-induced desaturation is common and may require early supplemental oxygen therapy. 3

Rule Out Infection First

• Obtain blood cultures, sputum cultures, and consider bronchoalveolar lavage if fever persists, as infection must be excluded before attributing symptoms to autoimmune disease alone. 4
• Test for atypical pathogens and opportunistic infections given the immunologic dysfunction suggested by positive ANA. 4

Define the Autoimmune Process

• Send comprehensive autoimmune serologies including anti-dsDNA, anti-Sm, anti-Ro/La, anti-Scl-70, anti-Jo-1, and rheumatoid factor to determine if criteria for a specific connective tissue disease are met. 5
• Document the ANA titer precisely, as titers ≥1:1280 in AIF-ILD are associated with improved survival compared to lower titers. 5
• Review for specific clinical features: Raynaud phenomenon, inflammatory arthritis, photosensitive rash, sicca symptoms, proximal muscle weakness, or skin thickening. 5

Risk Stratification Based on Lung Function

Very Severe ILD (VC ≤1.5L or DLCO ≤50%)

• All pregnancies with very severe ILD experienced adverse pregnancy outcomes in the largest cohort study, including a 60% rate of severe complications. 2
• Hospitalize for close monitoring with continuous pulse oximetry and daily assessment of respiratory status. 3
• Initiate supplemental oxygen immediately if oxygen saturation falls below 92% at rest or with minimal exertion. 3

Severe ILD (DLCO 50-60% or VC 1.5-2.0L)

• 56% of pregnancies with severe ILD had adverse outcomes, requiring intensive outpatient monitoring at minimum. 2
• Arrange weekly pulmonology follow-up with serial PFTs each trimester. 1

Mild-Moderate ILD

• 23% of pregnancies with mild-moderate ILD had adverse outcomes, but maternal morbidity remained low. 2
• Monitor with PFTs each trimester and maintain close communication between pulmonology and obstetrics. 1

Pharmacologic Management

If Infection is Excluded and Autoimmune Disease Confirmed

Initiate systemic corticosteroids immediately for active inflammatory ILD in pregnancy, as uncontrolled disease poses greater risk than medication exposure. 6, 3

• Prednisone 0.5-1 mg/kg/day or equivalent is safe throughout pregnancy and should not be withheld. 6
• Five of nine pregnant women with restrictive lung disease required corticosteroids in a prospective series, with good maternal and fetal outcomes. 3

Medications to Avoid Absolutely

• Stop any antifibrotic agents (pirfenidone, nintedanib) immediately if the patient was taking them pre-pregnancy, as safety data are lacking. 1
• Methotrexate is absolutely contraindicated and must be discontinued if inadvertently continued. 7
• Avoid mycophenolate, cyclophosphamide, and other teratogenic immunosuppressants. 1

Safe Maintenance Options

• Azathioprine can be continued or initiated if additional immunosuppression beyond corticosteroids is needed, as it is safe throughout pregnancy. 7, 1
• Hydroxychloroquine should be continued if the patient has underlying lupus or other CTD, as it reduces disease activity without fetal harm. 1

Oxygen Supplementation Strategy

• Initiate supplemental oxygen for any oxygen saturation <92% at rest or with exertion, as exercise intolerance is common and early supplementation improves outcomes. 3
• Seven of nine women in one series required oxygen during delivery, though none required intubation. 3
• Arrange home oxygen therapy if desaturation occurs with activities of daily living. 3

Thromboprophylaxis

Administer pharmacologic VTE prophylaxis with low-molecular-weight heparin if the patient requires hospitalization, as pregnant women with inflammatory conditions have elevated thrombotic risk. 6, 8

Imaging Considerations

• Use ultrasound or non-contrast MRI for any additional imaging needs, avoiding ionizing radiation when possible. 6, 8
• Gadolinium-based contrast agents must be avoided throughout pregnancy. 6, 8

Delivery Planning

• Base the decision for cesarean delivery on obstetric indications and respiratory status, not on ILD diagnosis alone. 7
• Ensure oxygen availability in the delivery room and have anesthesia prepared for potential respiratory support. 3
• Monitor for volume overload in the immediate postpartum period, as three women in one series developed this complication that resolved with diuretics. 2

Critical Pitfalls to Avoid

• Do not delay treatment while awaiting complete serologic workup if the patient is clinically deteriorating—empiric corticosteroids are safe and potentially life-saving. 6, 3
• Do not withhold necessary interventions solely because of pregnancy, as maternal stability is essential for fetal well-being. 8, 1
• Do not assume all ILD in pregnancy is autoimmune—drug-induced ILD from medications administered during pregnancy must be considered. 4
• Do not discharge without establishing close outpatient follow-up with both pulmonology and maternal-fetal medicine. 1

Prognosis and Counseling

• Maternal mortality is extremely rare even with severe ILD, with no deaths reported in the largest contemporary cohort. 2
• Adequate fetal growth can be achieved even in women requiring oxygen supplementation, with all infants in one series at or above the 30th percentile. 3
• CTD-ILD carries higher risk than sarcoidosis, with 56% versus 23% adverse pregnancy outcome rates respectively. 2